Skip to main content

Research Repository

See what's under the surface

Advanced Search

An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study

Maher, Toby M.; Oballa, Eunice; Simpson, Juliet K.; Porte, Joanne; Habgood, Anthony; Fahy, William A; Flynn, Aiden; Molyneux, Philip L.; Braybrooke, Rebecca; Divyateja, Hrushikesh; Parfrey, Helen; Rassl, Doris; Russell, Anne-Marie; Saini, Gauri; Renzoni, Elisabetta; Duggan, Anne-Marie; Hubbard, Richard; Wells, Athol U; Lukey, Pauline T.; Marshall, Richard P.; Jenkins, R. Gisli

Authors

Toby M. Maher

Eunice Oballa

Juliet K. Simpson

Joanne Porte joanne.porte@nottingham.ac.uk

Anthony Habgood anthony.habgood@nottingham.ac.uk

William A Fahy

Aiden Flynn

Philip L. Molyneux

Rebecca Braybrooke

Hrushikesh Divyateja

Helen Parfrey

Doris Rassl

Anne-Marie Russell

Gauri Saini gauri.saini@nottingham.ac.uk

Elisabetta Renzoni

Anne-Marie Duggan

Richard Hubbard richard.hubbard@nottingham.ac.uk

Athol U Wells

Pauline T. Lukey

Richard P. Marshall

R. Gisli Jenkins gisli.jenkins@nottingham.ac.uk



Abstract

Background: Idiopathic Pulmonary Fibrosis (IPF) is a progressive, fatal condition with a variable disease trajectory. The aim of this study was to evaluate potential biomarkers that predict outcome for people with IPF.
Method: The PROFILE study is a large prospective longitudinal cohort of treatment naïve IPF patients. We adopted a two-stage discovery and validation design using the PROFILE cohort. For the discovery analysis 106 individuals were examined alongside 50 age and gender matched healthy controls. We undertook an unbiased, multiplex evaluation of 123 biomarkers. Promising, novel, markers were further evaluated by immunohistochemical assessment of IPF lung tissue. The validation analysis examined samples from 206 IPF subjects, from the remaining 212 IPF patients recruited to PROFILE Central England, and were used for replication of the biomarkers identified from the discovery analysis using singleplex assays. This study addressed the predictive power of selected biomarkers to identify individuals with IPF at risk of: 1) progression and 2) death. The PROFILE studies are registered on clinicaltrials.gov (PROFILE Central England NCT01134822; PROFILE Royal Brompton Hospital NCT01110694).
Findings: The discovery analysis identified four serum biomarkers (Surfactant Protein D, Matrix Metalloproteinase 7, CA19-9 and CA-125) suitable for replication. Histological assessment of CA19-9 and CA-125 established these proteins as markers of epithelial damage. Replication analysis confirmed that baseline values of SP-D (46.6ng/ml vs 34.6 ng/ml; p =0.002) and CA19-9 (53.7 U/ml vs 22.2 U/ml p

Journal Article Type Article
Journal Lancet Respiratory Medicine
Print ISSN 2213-2600
Electronic ISSN 2213-2619
Publisher Elsevier
Peer Reviewed Peer Reviewed
Volume 5
Issue 12
APA6 Citation Maher, T. M., Oballa, E., Simpson, J. K., Porte, J., Habgood, A., Fahy, W. A., …Jenkins, R. G. (in press). An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study. Lancet Respiratory Medicine, 5(12), doi:10.1016/S2213-2600(17)30430-7
DOI https://doi.org/10.1016/S2213-2600%2817%2930430-7
Keywords Interstitial lung disease, clinical trials, biomarker,
Publisher URL http://www.thelancet.com/journals/lanres/article/PIIS2213-2600(17)30430-7/fulltext
Copyright Statement Copyright information regarding this work can be found at the following address: http://eprints.nottingh.../end_user_agreement.pdf

Files

LRM R2 2017_clean.pdf (500 Kb)
PDF

Copyright Statement
Copyright information regarding this work can be found at the following address: http://eprints.nottingham.ac.uk/end_user_agreement.pdf





You might also like



Downloadable Citations

;